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Abstract
Background: 3-guanidinopropionic acid derivatives reduce body weight in obese, diabetic mice.
We have assessed whether one of these analogues, the aminoguanidine carboxylate BVT.12777,
opens KATP channels in rat insulinoma cells, by the same mechanism as leptin.
Results: BVT.12777 hyperpolarized CRI-G1 rat insulinoma cells by activation of KATP channels. In
contrast, BVT.12777 did not activate heterologously expressed pancreatic β-cell KATP subunits
directly. Although BVT.12777 stimulated phosphorylation of MAPK and STAT3, there was no effect
on enzymes downstream of PI3K. Activation of KATP in CRI-G1 cells by BVT.12777 was not
dependent on MAPK or PI3K activity. Confocal imaging showed that BVT.12777 induced a re-
organization of cellular actin. Furthermore, the activation of KATP by BVT.12777 in CRI-G1 cells
was demonstrated to be dependent on actin cytoskeletal dynamics, similar to that observed for
leptin.
Conclusions: This study shows that BVT.12777, like leptin, activates KATP channels in insulinoma
cells. Unlike leptin, BVT.12777 activates KATP channels in a PI3K-independent manner, but, like
leptin, channel activation is dependent on actin cytoskeleton remodelling. Thus, BVT.12777 appears
to act as a leptin mimetic, at least with respect to KATP channel activation, and may bypass up-
stream signalling components of the leptin pathway.
Background
ATP-sensitive K+ (KATP) channels are important regulators
of cell function, coupling energy metabolism with electri-
cal activity. KATP channels are comprised of two proteins,
derived from the sulphonylurea receptor (SUR) family
and an inwardly rectifying K+ channel (Kir6.x family), the
exact composition of these being dependent upon tissue
[1,2]. For example, pancreatic β-cells and insulin-secreting
clonal cell lines express KATP channels consisting of Kir6.2
and SUR1 subunits [3]. KATP  channels are present in
numerous tissues and are the target for drugs that inhibit
or increase channel activity [4,5]. The archetypal inhibi-
tors of these channels are the sulphonylurea class of drugs,
which bind to the SUR subunit of the channel. Modula-
tion of KATP channel activity in pancreatic β-cells has pro-
found effects on insulin secretion and glucose
homeostasis [6]. Sulphonylureas such as tolbutamide and
glibenclamide inhibit channel activity, resulting in β-cell
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depolarization, increased electrical activity, enhanced cal-
cium entry and consequently increased insulin secretion
[7]. In contrast, pancreatic β-cell KATP channel activation
induces hyperglycaemia in animals and man [8]. This lat-
ter action is caused by membrane hyperpolarization,
reduction in cell excitability and decreased intracellular
calcium resulting in reduced secretion of insulin. Such
effects have been reported following application of the
benzothiadiazine, diazoxide, which has been used on
occasion to treat persistent hyperinsulinemic hypoglycae-
mia of infancy [8]. It has been demonstrated that diazox-
ide interacts with the sulphonylurea receptor subunit,
SUR1, encompassing transmembrane domains 6–11 and
the first nucleotide binding fold [9]. A similar conclusion
has also been reached using a novel diazoxide analogue
[10]. The presence of KATP channels in many other tissues,
notably muscle and central neurons, has stimulated inter-
est in the development of novel, selective KATP channel
openers for the treatment of various diseases [10,11].
The ob gene product leptin has been demonstrated to acti-
vate KATP channels in pancreatic β-cells [12] and insulin-
secreting cell lines [13], consistent with a potential role in
modifying insulin secretion [14]. One of the primary
functions for this hormone is its role in the regulation of
food intake and body weight [15]. Interestingly, leptin
also activates KATP  channels of hypothalamic glucose-
responsive neurones [16,17] indicating a possible role for
this channel in the control of energy homeostasis and
body weight. In addition, Kir6.2 knock-out mice have def-
icits in central glucose sensing leading to loss of glucose
mediated feeding response and a defective hypoglycaemic
compensatory response [18]. These latter findings suggest
that hypothalamic KATP channels may also be an impor-
tant target for drug manipulation with respect to centrally
driven control of glucose and energy homeostasis. The
aminoguanidine carboxylate, BVT.12777 (Figure 1), is
one of a series of structurally related molecules based on
the anti-diabetic/anti-obesity agent 3-guanidinopropi-
onic acid [19], which, like leptin, have been demonstrated
to reduce body weight in obese diabetic (ob/ob) mice [20].
Here we demonstrate that BVT.12777 opens KATP channels
in the CRI-G1 insulin secreting cell line, a useful model
for pancreatic β-cells [21], and for analysing the mecha-
nism by which leptin opens KATP channels [13,22,23].
Results
BVT.12777 activates KATP channels
Under current clamp conditions with 5 mM ATP in the
pipette solution to maintain KATP channels in the closed
state, the mean resting potential was -38.7 ± 1.7 mV (n =
10), similar to values reported in previous studies [13,22]
under these recording conditions. Application of
BVT.12777 (100 µM) hyperpolarized CRI-G1 cells (Figure
2A) to -66.3 ± 2.7 mV (n = 10). Examination of the volt-
age-clamped macroscopic currents indicates that prior to
the addition of BVT.12777 the slope conductance of the
cells was 0.43 ± 0.03 nS (n = 10), and following exposure
to BVT.12777 (100 µM), this increased to 3.45 ± 1.17 nS
(n = 10). The reversal potential (obtained from the point
of intersection of the current-voltage relationship) associ-
ated with the BVT.12777-induced conductance increase
(Figure 2A) was -78.5 ± 0.8 mV (n = 10), close to the cal-
culated value for Ek of -84 mV in this system, indicating
increased K+  conductance. CRI-G1 cells responded to
BVT.12777 in an all or none manner, with cells undergo-
ing full hyperpolarization and increase in conductance, at
all concentrations (100 – 300 µM) examined. Such an
effect has also been reported for leptin on CRI-G1 cells
[13]. Removal of BVT.12777 from the bath solution did
not fully recover the membrane potential and conduct-
ance to control values over the next 15–30 minutes (not
shown). Application of the KATP channel inhibitor, tolb-
utamide (100 µM) during BVT.12777 exposure (Figure
2A) completely reversed the BVT.12777-induced hyper-
polarization and decreased conductance, to -41.0 ± 4.8
mV (n = 5) and 0.58 ± 0.07 nS (n = 5) respectively, values
indistinguishable from control (P > 0.05). These data
indicate that BVT.12777 increases KATP current in this cell
line. This is demonstrated more clearly in cell-attached
recordings from CRI-G1 cells, where bath application of
BVT.12777 (100 µM) resulted in activation of single KATP
channel currents (Figure 2B; n = 7). The increase in chan-
nel activity was evident within 5 minutes of drug applica-
tion, was sustained over the time course of exposure (~30
minutes) and was not immediately reversed following
removal of the drug. Figure 2C shows mean channel activ-
ity (Nf.Po), normalised to the control for each recording,
plotted against time of exposure to BVT.12777.
BVT.12777 activation of KATP channels was demonstrated
to be reversibly inhibited by 100 µM tolbutamide (n = 4;
Structure of BVT.12777 Figure 1
Structure of BVT.12777 ([2-(hydrazinoiminomethyl)-
hydrazino] acetic acid)
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Figure 2B,2C). Identical control experiments, in the
absence of BVT.12777, resulted in no significant effect on
KATP channel activity, over a 30-minute test period (n = 8;
P > 0.05).
The effect of BVT.12777 on KATP  channel activity in
excised membrane patches was also examined. Record-
ings were made from inside-out patches in symmetrical
(140 mM KCl in pipette and bath solutions) K+ at a mem-
brane potential of -40 mV. KATP channels were identified
by inhibition of channel activity following application of
100  µM MgATP to the inner membrane aspect of the
patch, which reduced normalised NfPo from 1.0 to 0.23 ±
0.05 (n = 4; P < 0.05). Subsequent application of 100 µM
BVT.12777, in the continued presence of MgATP, induced
a gradual increase in KATP channel activity (Figure 3), to
levels similar to that of control (in the absence of MgATP).
For example 15 minutes after 100 µM BVT.12777 applica-
tion normalised mean channel activity had recovered to
1.18 ± 0.46 (n = 4). In experiments where no drug was
added, KATP channel currents, in the presence of 100 µM
MgATP, did not activate spontaneously (n = 4).
BVT.12777 activates KATP channels independently of PI 3-
kinase activity
Leptin and diazoxide hyperpolarized CRI-G1 cells, in a
manner similar to that of BVT.12777 (data not shown).
Leptin (10 nM) induced a hyperpolarization from a mean
membrane potential of -47.6 ± 1.6 mV to -68.5 ± 1.9 mV
(n = 8; P < 0.05), and application of tolbutamide (100
µM) reversed this action, returning the membrane poten-
tial to -47.5 ± 1.9 mV (n = 4). Diazoxide (200 µM) rapidly
hyperpolarized CRI-G1 cells from a mean membrane
potential of -49.9 ± 1.7 mV to -74.0 ± 1.5 mV (n = 6; P <
0.05), with tolbutamide (100 µM) also reversing this
action, returning membrane potential to -46.9 ± 3.8 mV
(n = 6). Leptin, but not diazoxide activation of CRI-G1
KATP channels is PI3K dependent [22,23]. Thus, we inves-
tigated whether BVT.12777 activates KATP channels in CRI-
G1 cells by direct (like diazoxide) or indirect (like leptin)
mechanisms.
Pre-incubation of CRI-G1 cells (20 min) with inhibitors
of PI 3-kinase, wortmannin (10 nM) or LY294002 (10
µM) had no significant effect on the mean resting mem-
brane potential or slope conductance of CRI-G1 cells and
did not prevent BVT.12777 from causing hyperpolariza-
tion and increased cell conductance (Figure 4A). In the
presence of 10 nM wortmannin, values for mean mem-
brane potential and slope conductance were -44.3 ± 1.2
mV (n = 6) and 0.86 ± 0.10 nS (n = 5), and addition of
200 µM BVT.12777 hyperpolarized cells to -68.9 ± 0.8 mV
(n = 6) with an increase in slope conductance to 3.10 ±
0.38 nS (n = 5). Identical results were obtained in the pres-
ence of 10 µM LY294002 (data not shown), with corre-
sponding control values of -40.8 ± 2.8 mV (n = 6) and
0.79 ± 0.11 nS (n = 4), and in the presence of 200 µM
BVT.12777, -67.9 ± 0.6 mV (n = 6) and 2.69 ± 0.35 nS (n
= 4) for membrane potential and slope conductance
respectively. In all experiments (i.e with either PI3K inhib-
itor) addition of tolbutamide (100 µM) recovered the
membrane potential (-41.8 ± 1.5 and -34.0 ± 1.7 mV; n =
6) and slope conductance (0.89 ± 0.11 (n = 5) and 0.58 ±
0.06 (n = 4) nS) for wortmannin and LY294002 respec-
tively, to values indistinguishable from controls (P > 0.1).
Cell-attached recordings from CRI-G1 cells also show that
wortmannin (10 – 100 nM) did not occlude BVT.12777
activation of KATP channels (Figure 4B). Mean channel
activity in the presence of wortmannin (10 nM) was 0.02
± 0.00 which increased to 0.16 ± 0.02, 20 minutes after
exposure to 100 µM BVT.12777 (n = 3; P < 0.05). Control
experiments where no BVT.12777 was added show no
change in channel activity over a 30-minute period (Nf.Po
= 0.01 ± 0.00 and 0.04 ± 0.00 after 5 and 30 minutes
respectively; n = 4).
Heterologously expressed KATP currents are not activated 
by BVT.12777
Oocytes injected with Kir6.2 and SUR1 cRNAs were chal-
lenged with sodium azide (3 mM) to elicit a reversible
increase in current, which was completely blocked by 1
µM glibenclamide or 0.5 mM tolbutamide, indicating that
the current was due to KATP activation, as described previ-
ously [24,25]. In oocytes, previously exposed to sodium
azide in order to verify Kir6.2-SUR1 expression, applica-
tion of BVT.12777 (10 µM – 1 mM) did not produce any
consistent increase in KATP  current (n = 16; data not
shown). Consequently, we utilized an alternative expres-
sion system, the HEK 293 cell line [25]. Application of
BVT.12777 (100 µM) to the bathing solution using the
cell-attached recording configuration resulted in no
significant increase in mean channel activity above con-
trol levels over a 30-minute period, although subsequent
addition of sodium azide (3 mM) did cause a rapid
increase in channel activity, which was reversed by the
addition of 100 µM tolbutamide (n = 4, data not shown).
Similarly, application of BVT.12777 in the presence of 0.1
mM MgATP to inside-out patches from HEK 293 cells
transiently expressing Kir6.2-SUR1, did not cause activa-
tion of channel activity following 30 minutes exposure (n
= 4; data not shown). Thus BVT.12777 does not appear to
be capable of activating heterologously expressed Kir6.2-
SUR1 currents.
MAPK does not mediate BVT.12777-activation of KATP
Exposure of CRI-G1 cells to BVT.12777 (100 µM) for up
to 30 minutes had no consistent effect on the phosphor-
ylation of enzymes downstream of PI3K (PKB and its
downstream target, GSK3), but did increase the phospho-
rylation of STAT3 (n = 4) and MAPK (n = 4; data notBMC Pharmacology 2004, 4:17 http://www.biomedcentral.com/1471-2210/4/17
Page 4 of 13
(page number not for citation purposes)
BVT.12777 activates a tolbutamide-sensitive K+ current Figure 2
BVT.12777 activates a tolbutamide-sensitive K+ current A, the upper trace shows a current clamp recording of a CRI-
G1 cell following dialysis with a 5 mM ATP-containing solution. In this and subsequent current clamp figures the trace begins 
approximately 5 min after formation of the whole-cell configuration. Application of BVT.12777 (100 µM) for the time indicated 
hyperpolarized the cell from -50 mV to -76 mV, an action readily reversed by tolbutamide (100 µM), which returned mem-
brane potential to -54 mV. Washout of all drugs from the bath resulted in a membrane potential of -70 mV, indicating the lack 
of reversibility of BVT.12777. The lower plot is the current-voltage relationship for the voltage clamped currents. Cells were 
voltage clamped at -50 mV and 10 mV steps of 100 ms duration were applied every 200 ms (range -120 to -30 mV). BVT.12777 
increased the membrane conductance relative to control and tolbutamide reversed this BVT.12777-induced conductance 
increase with a reversal potential of -78 mV. B, cell-attached recording from a CRI-G1 cell, at 10 mV applied to the recording 
pipette. Single channel openings are shown as downward deflections. Addition of 100 µM BVT.12777 induced an increase in 
channel activity (Nf.Po) from 0.17 in control to 0.31, and 1.25 at 10 and 20 minutes respectively, after BVT addition. Application 
of 100 µM tolbutamide induced a substantial inhibition of activity (to 0.02), which was reversed on washout of all drugs, with 
activity increasing to 0.74. The symbol C refers to the closed state of the channel in this and subsequent figures. C, diary plot of 
Nf.Po against time from cell-attached experiments in the presence and absence of BVT.12777, where channel activity was calcu-
lated every 2 minutes. Each point is the mean of 4–7 separate determinations.BMC Pharmacology 2004, 4:17 http://www.biomedcentral.com/1471-2210/4/17
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shown). These data are in agreement with the lack of
BVT.12777 sensitivity to PI3K inhibitors on activation of
KATP channels. However, activation of MAPK has been
implicated as a significant intermediate for both insulin
and leptin signalling pathways in various cell types [26-
29]. Thus, we examined the effect of UO126, a potent and
specific inhibitor of the activation of the classical MAPK
cascade [30], on BVT.12777 opening of KATP channels.
Application of UO126 (25 µM) inhibited approximately
90 % of KATP channel activity in cell-attached or inside-out
recordings, whereas 1–10 µM UO126, concentrations that
suppresses activation of MAPKK [30], had no significant
effect on channel activity (data not shown). Control cell
attached recordings had a mean channel activity of 0.07 ±
0.02, which increased to 1.29 ± 0.82 (n = 3) in the pres-
ence of BVT.12777 (100 µM). Subsequent application of
UO126 (1 µM) in the continued presence of BVT.12777
did not alter channel activity (data not shown), over a 15-
minute period (Nf.Po was 1.86 ± 1.45 (n = 3) and 2.44 ±
2.00 (n = 3), at 5 and 15 minutes respectively; P < 0.05).
BVT.12777 activates KATP channels in inside-out patches Figure 3
BVT.12777 activates KATP channels in inside-out patches Continuous single channel currents recorded from an inside-
out patch at a holding potential of -40 mV. Application of 100 µM MgATP reversibly inhibited channel activity by >90%, demon-
strating KATP identity. Addition of 100 µM BVT.12777, in the presence of 100 µM MgATP to the cytoplasmic aspect of the 
patch resulted in KATP channel activation. Nf.Po values were 2.96 (control, after first MgATP challenge), and 0.25 in the pres-
ence of MgATP, which increased to 0.72, 1.06 and 2.74 at 5, 10 and 20 minutes respectively, after BVT.12777 addition.
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Wortmannin does not inhibit BVT.12777 activation of KATP Figure 4
Wortmannin does not inhibit BVT.12777 activation of KATP A, current clamp record of a CRI-G1 cell dialysed with 5 
mM MgATP, following exposure of cells to 10 nM wortmannin for 15–20 minutes. Application of BVT.12777 (200 µM), in the 
continued presence of wortmannin hyperpolarized the cell from -46 to -77 mV. Tolbutamide (100 µM), applied after the BVT-
induced hyperpolarization, recovered the membrane potential (to -40 mV). B, cell-attached recordings from CRI-G1 cells, fol-
lowing exposure of cells to 10 nM wortmannin for 15–20 minutes. Upper trace; in the continued presence of wortmannin, 
Nf.Po was 0.01 and 0.03 after 5 and 30 minutes respectively. Lower trace, application of BVT.12777 (100 µM) to cell-attached 
recording in the presence of 10 nM wortmannin resulted in KATP activation, with Nf.Po values of 0.01, 0.12 and 0.27 prior to, 
and 10 and 30 minutes after, BVT.12777, respectively. Addition of 100 nM wortmannin did not inhibit channel activity.
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In addition, increasing UO126 to 10 µM had no effect on
BVT.12777 induced KATP channel activation.
BVT.12777 activation of KATP channels is dependent on 
actin cytoskeleton dynamics
Leptin activation of KATP channels in the CRI-G1 cell line
is dependent upon reorganisation of the cytoskeleton, a
process downstream from PI3K activation [31]. Therefore,
we examined whether BVT.12777 opening of CRI-G1 KATP
channels occurs through alteration of actin filament
dynamics. For this series of experiments the heptapeptide
mushroom toxin phalloidin [32] was used to stabilise the
polymerised form of actin (F-actin). As phalloidin is
membrane-impermeant, it was directly applied to the
internal aspect of the cell membrane. In whole-cell exper-
iments, 10 µM phalloidin was added to the electrode solu-
tion and allowed to dialyse into the cell. The mean resting
potential and slope conductance were -38.0 ± 0.6 mV and
0.66 ± 0.04 nS (n = 4) respectively, and following addition
of 200 µM BVT.12777 no significant change in these
parameters was observed (Figure 5A), with a mean mem-
brane potential of -41.7 ± 1.1 mV and slope conductance
of 0.60 ± 0.08 nS (n = 4; P > 0.05). The presence of phal-
loidin (10 µM) in the bath solution also prevented KATP
channel activation by BVT.12777 in the inside-out iso-
lated patch configuration (Figure 5B). Application of 0.1
mM MgATP to the cytoplasmic aspect of inside-out
patches caused 97.5 ± 2.1% inhibition of KATP channel
activity (n = 3; P < 0.05) and subsequent addition of 10
µM phalloidin had no further effect, as reported previ-
ously [29]. Subsequent addition of BVT.12777 (100 µM)
failed to increase KATP channel activity, with mean Nf.Po
values of 0.06 ± 0.05 and 0.03 ± 0.01 in the absence and
presence of BVT.12777 respectively (n = 3; P > 0.05). In
contrast, the direct KATP channel opener, diazoxide acti-
vates KATP  channels in the presence of phalloidin. In
whole-cell experiments (Figure 5C), diazoxide (200 µM)
hyperpolarized CRI-G1 cells from a mean membrane
potential of -42.6 ± 0.1 mV to -70.1 ± 0.8 mV (n = 4; P <
0.05), and increased slope conductance from 0.87 ± 0.23
to 7.39 ± 0.72, actions reversed by tolbutamide (100 µM).
F-actin is disrupted by BVT.12777
The prevention of BVT.12777-induced KATP activation by
phalloidin mirrors the effect of this toxin on leptin activa-
tion of KATP [31]. Thus, we visualised F-actin by staining
with rhodamine-conjugated phalloidin. In untreated CRI-
G1 cells there was pronounced phalloidin-positive label-
ling of the cell membrane, with more diffuse, granular
staining within the cytoplasm (Figure 6A). In contrast,
cells treated with BVT.12777 (100 µM) or leptin (10 nM)
for 40 min showed a marked reduction in phalloidin flu-
orescence intensity, with disjointed labelling at the cell
membrane (Figure 6A). The actin filament disrupter cyto-
chalasin B [33] also reduced the intensity of phalloidin
labelling but in a more punctate manner on visualisation
of treated cells compared with controls (data not shown).
Analysis of the mean fluorescence intensity at the cell
membrane following the actions of BVT.12777 and leptin
demonstrated that both treatments caused a significant
reduction of the intensity of rhodamine-phalloidin label-
ling, by 43.0 ± 4.2% (n = 6; P < 0.05) and 62.2 ± 6.0% (n
= 6; P < 0.05), respectively, compared to untreated cells
(Figure 6B). However, the directly acting KATP channel
opener, diazoxide did not cause disruption of the actin
cytoskeleton (Figure 6A,6B), with a relative intensity of
rhodamine-phalloidin staining of 0.98 ± 0.16 (P > 0.05).
Discussion
BVT.12777 induced hyperpolarization of CRI-G1 cells,
with an associated increase in K+ conductance, an action
likely caused by the activation of KATP channels, as the
sulphonylurea tolbutamide completely reversed its
effects. Cell-attached and inside-out single channel cur-
rent recordings demonstrate directly that BVT.12777
activates KATP channels. The increased KATP current gener-
ated in isolated membrane patches resembles the effects
of KATP activators such as diazoxide [34] and sodium azide
[35], which have also been shown to activate insulinoma
or pancreatic β-cell KATP channels in isolated patches in
the presence of Mg-ATP. Thus, although not tested here,
BVT.12777 as an activator of KATP would be expected, as
observed for diazoxide, to inhibit insulin release from
CRI-G1 cells stimulated by metabolizable substrates or
tolbutamide [36], although this would clearly be depend-
ent on its action on other β-cell conductances, notably cal-
cium channels. BVT.12777 activation of KATP channels
was only slowly reversed on withdrawal of the drug,
unlike the actions of diazoxide or sodium azide, which are
rapidly reversed on washout [35,36]. Indeed, following
removal of BVT.12777 in the absence or presence of
tolbutamide, enhanced KATP channel activity was apparent
for a considerable time. The slow reversibility on washout
of BVT.12777 resembles the effects of the hormone leptin
on CRI-G1 cell membrane potential and KATP channel
activation [13].
Leptin, via activation of the main signalling form of the
leptin receptor (ObRb), has been shown to increase the
phosphorylation of STAT3, MAPK and to stimulate PI3K
pathways in various peripheral tissues, cell lines [37], and
in hypothalamic neurones [38]. BVT.12777 although
stimulating phosphorylation of STAT3 and MAPK did not
stimulate PI3K dependent pathways as demonstrated by
the lack of effect on the phosphorylation status of the
PI3K output indicators, PKB and GSK3. It is unclear at
present how this molecule induces STAT3 and MAPK
phosphorylation. As KATP activation by BVT.12777 is rapid
and occurs in isolated membrane patches it is unlikely
that any JAK-STAT pathway (which drives changes in tran-BMC Pharmacology 2004, 4:17 http://www.biomedcentral.com/1471-2210/4/17
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Phalloidin prevents BVT.12777 activation of KATP Figure 5
Phalloidin prevents BVT.12777 activation of KATP A, current clamp record of a CRI-G1 cell dialysed with 5 mM MgATP 
and 10 µM phalloidin. Application of BVT.12777 (200 µM) had no effect on the membrane potential of the cell (-41 mV) in the 
presence of phalloidin. B, continuous single channel currents recorded from an inside-out patch at a holding potential of -40 
mV. Application of 100 µM MgATP reversibly inhibited Nf.Po from 1.25 to 0.02. Addition of 10 µM phalloidin and subsequently 
100 µM BVT.12777, in the presence of 100 µM MgATP, to the cytoplasmic aspect of the patch resulted in no effect on KATP, 
with Nf.Po values of 0.01 and 0.03 respectively. C, current clamp record of a CRI-G1 cell dialysed with 5 mM MgATP and 10 µM 
phalloidin. Application of diazoxide (200 µM) induced rapid cell membrane hyperpolarization, from -55 to -72 mV, an action 
reversed (to -45 mV) by tolbutamide (100 µM).BMC Pharmacology 2004, 4:17 http://www.biomedcentral.com/1471-2210/4/17
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scription) contributes to this action. Leptin activation of
KATP channel currents in CRI-G1 cells has previously been
shown to be independent of MAPK, but prevented by the
inhibitors of PI3K [22]. However, BVT.12777 activation
was not only insensitive to inhibition by the MAPKK
inhibitor, UO126, it was also insensitive to the presence
of the PI3-kinase inhibitors, wortmannin and LY294002,
at concentrations sufficient to prevent leptin activation of
KATP in this cell line. These data led us to suspect that
BVT.12777, irrespective of its ability to initiate various sig-
nalling cascades in this cell line, increased KATP channel
activity by a more direct effect on the channel subunits in
a manner analogous to diazoxide, which is purported to
interact directly with the SUR1 subunit [9,10]. This possi-
bility was tested by heterologous expression of the β-cell
subunits of KATP channels, Kir6.2 and SUR1, in Xenopus
oocytes, a commonly utilised expression system for elec-
trophysiological studies of these recombinant channels
[24,25]. However, BVT.12777 did not activate Kir6.2-
SUR1 currents in oocytes, demonstrated to express
functional KATP channel currents. Thus we explored this
question further by utilising a second heterologous
expression system for Kir6.2-SUR1, HEK293 cells. Record-
ings from inside-out patches demonstrated that
BVT.12777 did not activate Kir6.2-SUR1 currents in the
presence of Mg-ATP, in contrast to diazoxide [39] or
BVT.12777 disrupts the actin cytoskeleton Figure 6
BVT.12777 disrupts the actin cytoskeleton A, images of rhodamine-conjugated phalloidin fluorescence in CRI-G1 cells in 
control conditions and following incubation with leptin (10 nM), BVT.12777 (100 µM) or diazoxide (200 µM) for 30 minutes. 
All panels show representative X-Y images. Note the marked reduction in phalloidin staining in cells pre-treated with leptin or 
BVT.12777, and not diazoxide. Scale bars are 50 µm. B, histogram comparing the normalised fluorescence intensity relative to 
control in the membrane periphery of randomly selected CRI-G1 cells for each condition; (control (n = 13; cells = 195), 10 nM 
leptin (n = 6; cells = 90), BVT.12777 (n = 6; cells = 90) and 200 µM diazoxide (n = 4, cells = 60). Error bars indicate s.e.m. and 
* significance of P < 0.001.
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sodium azide [35]. Overall these data strongly suggest that
expression of the KATP channel subunits, Kir6.2 and SUR1
are insufficient per se to bring about sensitivity to
BVT.12777, and indicate that this opener may activate this
channel type by an indirect mechanism (which is not
available in oocytes or HEK cells).
Although the activation of KATP channels by leptin in CRI-
G1 cells is PI3-kinase dependent the lipid products of this
enzyme system, such as PtdIns(3,4,5)P3 also do not inter-
act directly with KATP channels [22]. Recent studies dem-
onstrate that both leptin and PtdIns(3,4,5)P3  increase
KATP  channel activity indirectly, through changes in
cytoskeletal dynamics [31]. It is well established that
many ion channels and transporters are anchored in the
membrane by either direct or indirect association with the
cytoskeleton. In addition, there is growing evidence that
altering the integrity of cytoskeletal elements, in particular
actin filaments, can modulate the activity of a variety of
ion channels [40] and receptors [41]. For example, disrup-
tion of actin filaments with cytochalasin is shown to
increase KATP channel activity in cardiac myocytes [42]
and CRI-G1 cells [31]. Indeed, a number of lipid kinases,
including PI 3-kinase, are also localised to the cytoskele-
ton and their activities are modulated by a variety of
cytoskeletal proteins, especially those associated with
actin [40]. Actin filament structure is controlled by revers-
ible polymerisation of G-actin, which forms F-actin, and
this process is under the dynamic control of various actin-
binding proteins [43]. The heptapeptide mushroom toxin
phalloidin [32] binds to filamentous F-actin with high
affinity and stabilises the actin in this form. The addition
of phalloidin to the intracellular aspect of CRI-G1 cells
prevented BVT.12777, but not diazoxide, from activation
of KATP channel currents in whole cell and inside out
recording configurations indicating that this molecule
likely causes the opening of KATP channels by a membrane
delimited alteration of cytoskeletal dynamics. This mech-
anism of action is identical to that proposed for leptin and
PtdIns(3,4,5)P3 activation of KATP in this cell line [31]. Flu-
orescence staining of CRI-G1 cells with rhodamine-conju-
gated phalloidin revealed disassembly of actin filaments
by both BVT.12777 and leptin, but not diazoxide. These
data provide direct support for an important role for
cytoskeletal dynamics in the control of KATP channel activ-
ity by both leptin and BVT.12777. The lack of effect of dia-
zoxide on the actin filament structure is also supportive of
this opener acting directly on the KATP channel subunits.
Conclusions
BVT.12777 activation of KATP channels in CRI-G1 cells was
evident regardless of whether it was applied to the external
or internal surface of the cell. BVT.12777 signalling to
KATP channels is not mediated by PI 3-kinase or MAPK, but
does appear to depend on actin filament re-modelling. As
leptin hyperpolarizes a sub-population of hypothalamic
neurones by opening KATP channels [16], it is feasible that
at least part of the anti-obesity action of BVT.12777 may
be through the activation of this potassium channel. Fur-
thermore, as BVT.12777 acts downstream of PI3K, such an
agent may act to overcome the putative central leptin
resistance associated with the obese state [37]. Thus,
although BVT.12777 and its close structural analogues are
unlikely per se to be useful anti-obesity agents as they dis-
play hepatotoxicity [44], understanding the general prin-
ciples underlying their mechanism of action may reveal
clues for future anti-obesity drug development.
Methods
Cell culture and transfection
Cells from the insulin secreting cell line, CRI-G1, and the
human embryonic kidney cell line, HEK 293, were grown
as described previously [25,35]. The preparation of mouse
Kir6.2 (provided by Professor F. Ashcroft, University of
Oxford), rat SUR 1 (provided by Dr G. Bell, University of
Chicago) and CD4 cDNAs and transfection procedures
were as described by [25]. Transfected cells were selected
by visible binding of anti-CD4 coated beads (Dynal,
Oslo) following incubation with the beads for 20 min.
Oocyte collection and preparation
Ovarian lobes were removed from mature female Xenopus
laevis frogs (Blades Biological, UK) following killing of the
animal by destruction of the brain. The use of animals was
in accordance with the Home Office Animals (Scientific
Procedures) Act (1986) and approved by the local ethics
committee. Separation and selection of oocytes and the
preparation and injection of cRNAs were performed as
described by [25].
Western blotting
CRI-G1 cells, in normal saline (containing in mM; NaCl
135, KCl 5, MgCl2 1, CaCl2, 1, HEPES 10 with glucose 10
(pH 7.4) were treated with BVT.12777 (100 µM) for 0, 1,
5, 15 or 30 minutes and whole-cell extracts were prepared
as described [23]. Proteins (10 µg) were suspended in
loading buffer (Invitrogen) and after denaturation,
loaded on to NuPage 4–12% Bis-Tris mini-gels (Invitro-
gen) and run at 200 V for 1 hr. Subsequently, proteins
were transferred to Hybond-C Extra nitrocellulose mem-
branes (Amersham) at 25 V for 80 minutes at room tem-
perature. Membranes were incubated in blocking buffer
(5% non-fat milk in TBST (20 mM Tris HCl, 150 mM
NaCl, 0.5% Tween, pH 7.4)) for 1 hr at room temperature
after which antibodies to phospho-MAPK, phospho-
STAT3, phospho PKB, phospho-GSK3 and PKB (all at
1:1000) were applied at 4°C with gentle shaking, over-
night. The membranes were washed with TBST (4 × 30
minutes) and incubated for 1 hr at room temperature with
HRP conjugated ImmunoPure goat anti-rabbit IgGBMC Pharmacology 2004, 4:17 http://www.biomedcentral.com/1471-2210/4/17
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(1:5000). After washing with TBST (5 × 15 minutes),
immunoreactive bands were visualised by the enhanced
chemiluminescence (ECL) detection reagent
(Amersham).
Cytoskeletal fluorescence imaging and analysis
CRI-G1 cells were gently washed in normal saline (con-
taining in mM): NaCl 135, KCl 5, MgCl2 1, CaCl2 1,
HEPES 10, pH 7.4, and incubated for 40 min with either
100 µM BVT.12777, 10 nM leptin, 200 µM diazoxide or 3
mM sodium azide for 30 min with the cytoskeletal dis-
rupter, cytochalasin B (10 µM). Cells were then fixed, per-
meabilised, stained with rhodamine-conjugated
phalloidin (2.66 U ml-1) and visualised using a BioRad
Microradiance, confocal imaging system as described by
[31]. The intensity of rhodamine-conjugated phalloidin
staining in the plasma membrane was determined using
BioRad Lasersharp processing software (Bio-Rad, CA,
USA). Analysis lines were drawn along randomly selected
regions of the plasma membrane and the fluorescence
intensity determined. A histogram giving the mean fluo-
rescence intensity was constructed for a minimum of 5
cells on each stimulated or control dish on at least 3 sep-
arate occasions. Within a given experimental series all
conditions for capturing images were constant. In order to
allow for quantification of experimental data obtained on
separate days, the results were normalised relative to the
mean plasma membrane fluorescence measured in the
control cells for each day and presented as mean ± S.E.M.
Statistical analyses were performed using Student's
unpaired t test. p < 0.05 was considered significant.
Electrophysiological recording and analysis
Whole cell currents from Xenopus oocytes were measured
using a two-electrode voltage clamp technique as
described by [25]. Recordings were made in a high-potas-
sium bath solution, KD96 containing (mM): KCl 96,
NaCl 2, CaCl2 1.8, HEPES 5 (pH 7.4 with KOH). Working
concentrations of drugs were prepared in KD96 and
superfused into the bath. Whole-cell current-clamp
recordings with excursions to voltage clamp mode were
used to monitor membrane potential and macroscopic
currents from CRI-G1 cells. Cell-attached and excised
inside-out recordings were made from CRI-G1 cells and
HEK cells expressing Kir6.2 and SUR1 to examine single
channel responses as described previously [25,35]. Single
channel data were analysed for current amplitude and
channel activity (Nf.Po; where Nf is the number of func-
tional channels in the patch and Po is the open probabil-
ity) as described previously [45]. All data were normalised
to control and are expressed as mean ± S.E.M. Statistical
analyses were performed using Student's unpaired t test. P
< 0.05 was considered significant. Recording electrodes
were pulled from borosilicate glass and had resistances of
2–5 MΩ for whole cell recordings and 7–10 MΩ for cell-
attached and inside-out experiments when filled with
electrolyte solution. The pipette solution for whole-cell
recordings comprised (in mM): KCl 140, MgCl2 0.6, CaCl2
2.73, Mg-ATP 5.0, EGTA 10, HEPES 10, pH 7.2 (free
[Ca2+] of 100 nM), whereas for single channel recordings
the pipette solution contained (in mM): KCl 140, CaCl2 1,
MgCl2 1, HEPES 10, pH 7.2. The bath solution for whole-
cell and cell-attached recordings was normal saline
whereas for inside-out patches the bath solution con-
tained (in mM): KCl 140, MgCl2 1, CaCl2 2, EGTA 10,
HEPES 10, pH 7.2 (free [Ca2+] of 30 nM). All solution
changes were achieved by superfusing the bath with a
gravity feed system at a rate of 10 ml min-1, which allowed
complete exchange within 2 min. All experiments were
performed at room temperature (22–25°C).
Antibodies & drugs
Anti-PKB, which recognises all three isoforms of PKB, and
the phospho-specific PKB (Thr308), GSK3α/β (Ser21/9),
STAT3 (Tyr705) and p44/42 MAPK (Thr202/Tyr204)
antibodies were obtained from Cell Signalling Technol-
ogy Inc. Recombinant human leptin, wortmannin and LY
294002 were obtained from Novachem-Calbiochem and
BVT.12777 ([2-(hydrazinoiminomethyl) hydrazino] ace-
tic acid) was a gift from Biovitrum (Stockholm, Sweden).
Tolbutamide, Mg-ATP, diazoxide, sodium azide, phalloi-
din and cytochalasin B were obtained from Sigma. Rhod-
amine-conjugated phalloidin was obtained from
Molecular Probes and UO126 from Promega. BVT.12777
was prepared as a 100 mM stock solution in normal saline
and stored at -70°C prior to use. Leptin was prepared as a
10 µM stock solution in normal saline containing 0.2 %
bovine serum albumin as carrier. Rhodamine-conjugated
phalloidin (200 U ml-1) and LY 294002 (10 mM) were
stored as stock solutions in 1% methanol at -20°C.
Cytochalasin B was stored as a 10 mM stock solution, and
diazoxide and tolbutamide as 100 mM solutions, all in
DMSO at 2–4°C. Mg-ATP was stored at -20°C as a 100
mM solution in 10 mM HEPES (pH 7.2). Wortmannin
and UO126 were stored as 10 mM stock solutions in
Me2SO at -20°C.
List of abbreviations used
CRI-G1, Cambridge Rat Insulinoma-G1; GSK3, glycogen
synthase kinase-3; HEK293, human embryonic kidney
293; JAK, janus kinase; KATP, ATP-sensitive potassium;
Kir6.2, potassium channel inward rectifier-6.2; MAPK,
p42, p44 mitogen-activated protein kinase; MAPKK,
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tein kinase B; PI3K, phosphatidylinositol 3-kinase;
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